RSS Novo Nordisk: STEP UP Trial Achieves Primary Endpoint - Quick Facts

[Crax Bot]

Novo Nordisk (NVO) has announced the results from STEP UP, a phase 3b trial within the global STEP program. The trial successfully met its primary endpoint, demonstrating a statistically significant and superior weight loss at week 72 with the administration of 7.2 mg semaglutide compared to a placebo.

"We are delighted to report a 20.7% weight reduction and observe that 33% of patients achieved over 25% weight loss using semaglutide 7.2 mg," stated Martin Holst Lange, Executive Vice President for Development at Novo Nordisk. "The safety and tolerability profile was consistent with that of semaglutide 2.4 mg."

STEP UP is a comprehensive 72-week trial focusing on the efficacy and safety of subcutaneous semaglutide 7.2 mg in comparison to 2.4 mg semaglutide and a placebo, all administered once weekly. Anticipated results from another phase 3 trial, STEP UP T2D—which studies semaglutide 7.2 mg in adults with type 2 diabetes and obesity—are expected to be released in the coming months.

The material has been provided by InstaForex Company - www.instaforex.com

Click to read more...